Keywords: PF ها; BM; brain metastasis; AE; adverse event; CI; confidence interval; CTLA4; cytotoxic T-lymphocyte antigen-4; CT; computed-tomography; GPA; Graded Prognostic Assessment score; IORR; intracerebral objective response rate; IQR; interquartile range; NSCLC; nonâ
مقالات ISI PF ها (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: PF ها; kidney; carcinoma; renal cell; neoplasm invasiveness; fascia; mortality; MVI; microvascular invasion; OS; overall survival; PFS; progression-free survival; PS; pseudocapsule; RCC; renal cell carcinoma;
Keywords: PF ها; CT; chemotherapy; EBRT; external beam radiotherapy; EEC; endometrial endometrioid carcinoma; HGSOC; high-grade serous ovarian cancer; HR; hazard ratio; IQR; interquartile range; OS; overall survival; PbCT; platinum-based chemotherapy; PFS; progression-fre
Keywords: PF ها; GEP; gene expression profiling; PFS; progression free survival; DRP; drug response prediction; TT; Total therapy; IMWG; The International Myeloma Work Group; ASCT; autologous stem cell transplantation; MMSET-high; high expression levels of MMSET; MAF-high
Keywords: PF ها; AUC; area under the curve; CE; cost effectiveness; CEAC; cost-effectiveness acceptability curve; CI; confidence interval; DMSIC; Drug and Medical Supply Information Center; DRG; diagnosis-related group; DSA; deterministic sensitivity analysis; EGFR; epide
Keywords: PF ها; SPMs; second primary malignancies; EBR; external beam radiation; OAC; ophthalmic artery chemosurgery; ERG; electroretinogram; PFS; progression-free survival (an event included any treatment with enucleation, external beam radiation and OAC following compl
Keywords: PF ها; metastatic breast cancer; MBC; lobaplatin and gemcitabine; GL; lobaplatin and vinorelbine; NL; cisplatin and gemcitabine; GP; cisplatin and vinorelbine; NP; progression-free survival; PFS; overall survival; OS; response rate; RR; platinum-based compounds;
Keywords: PF ها; urinary bladder neoplasms; urothelium; urologic neoplasms; drug therapy; combination; mortality; BCa; bladder cancer; EORTC; European Organization for the Research and Treatment of Cancer; GC; gemcitabine and cisplatin; HD; high dose; MCAVI; methotrexate,
Keywords: PF ها; urinary bladder neoplasms; neoplasm invasiveness; neoplasm recurrence; local; BCG vaccine; mortality; BCG; bacillus Calmette-Guérin; CIS; carcinoma in situ; CR; complete response; DSS; disease specific survival; MIBC; muscle invasive bladder cancer; NMIB
Keywords: PF ها; BP; blood pressure; D; diopter; INS; initial nasal step; IOP; intraocular pressure; IPFS; initial parafoveal scotoma; MAP; mean arterial pressure; MvD; microvasculature dropout; OCTA; OCT angiography; OPP; ocular perfusion pressure; PFS; parafoveal scotom
Keywords: PF ها; ALA; α-linolenic acid; CLA; Conjugated linoleic acid; DPA; Docosapentaenoic acid; FADS1; Fatty acid desaturase-1; FADS2; Fatty acid desaturase-2; EPA; Eicosapentaenoic acid; GAPDH; Glyceraldehyde-3-phosphate dehydrogenase; LPL; Lipoprotein lipase; LA; Li
Keywords: PF ها; Chemotherapy; MBC; NLR; PFS; Prognosis;
Keywords: PF ها; PD-1; programed cell death-1; PD-L1; programmed cell death ligand 1; NSCLC; non-small-cell lung cancer; OS; overall survival; PFS; progression-free survival; ORR; objective response rate; irAEs; immune-related adverse events; RECIST; response evaluation c
Keywords: PF ها; BB; bevacizumab-bevacizumab; BP; bevacizumab followed by panitumumab; CA9; carbonic anhydrase 9; CRC; colorectal cancer; DEGs; differentially expressed genes; EGFR; epidermal growth factor receptor; EPHA2; ephrin type-A receptor 2; FASN; fatty acid syntha
Keywords: PF ها; biomarker; cancer outcome; cutaneous adverse event; cutaneous toxicity; oncodermatology; prognostic marker; survival; HFS; hand foot syndrome; HFSR; hand-foot skin reaction; HR; hazard ratio; irAE; immune-related adverse effect; NSCLC; non-small cell
Keywords: PF ها; BACE; bronchial arterial chemoembolization; CBM; China biological medicine database; CNKI; China national knowledge infrastructure database; CENTRAL; Cochrane Central Register of Controlled Trials; Chi-CTR; Chinese clinical trial registry; DCR; disease co
Keywords: PF ها; ABC; activated-B Cell; BTK; Bruton's tyrosine kinase; CNS; Central nervous system; CLL; chronic lymphocytic leukemia; DLBCL; Diffuse Large B-cell lymphoma; DAB; diaminobenzidin; DNMT; DNA methyltransferase; GO; gene ontology; GCB; germinal center cell lik
Keywords: PF ها; NSCLC; non-small cell lung cancer; RCTs; randomized controlled trials; OS; overall survival; PFS; progression free survival; ORR; objective response rate; AEs; adverse effects; HR; hazard ratio; RR; relative risk; CI; confidence intervals; FDA; Food and D
Keywords: PF ها; aBCC; advanced basal cell carcinoma; AE; adverse event; PI3K; phosphoinositide-3-kinase; PFS; progression free survival; SI; smoothened inhibitor;
Keywords: PF ها; AIHA; autoimmune hemolytic anemia; B2M; β2-microglobulin; BR; bendamustine and rituximab; BTK; Bruton tyrosine kinase; CLL; chronic lymphocytic leukemia; CR; complete remission; FCR; fludarabine; cyclophosphamide; and rituximab; FISH; fluorescence in sit
Keywords: PF ها; Brain neoplasm; Clinical trials; Glioblastoma; Immunotherapeutic; Immunotherapy; Vaccine; APC; Antigen-presenting cell; APVAC; Actively personalized vaccination; BBB; Blood-brain barrier; CMV; Cytomegalovirus; CNS; Central nervous system; CSF; Cerebrosp
Keywords: PF ها; AI; aromatase inhibitor; ASCO; American Society of Clinical Oncology; CDK4/6; cyclin-dependent kinase 4/6; DCIS; ductal carcinoma in situ; DFS; disease-free survival; ER; estrogen receptor; FDA; Food and Drug Administration; HER2; human epidermal growth f
Keywords: PF ها; Alzheimer's disease; Amyloid β-protein; Oligomers; Oligomeropathy; Aβ; amyloid β-protein; AD; Alzheimer's disease; ADDL; Aβ-derived diffusible ligands; AFM; atomic force microscopy; APP; Aβ precursor protein; APP OSK mice; APP transgenic mice express
Keywords: PF ها; head and neck cancer; OS; outcomes; PFS; PRO;
Keywords: PF ها; ALK; Anaplastic Lymphoma Kinase; CI; Confidence interval; CT; Computerized Tomography; EGFR; Epidermal Growth Factor Receptor; ESMO; European Society of Medical Oncology; 18F-FDG; Fluorodeoxyglucose; IQR; Interquartile range; MATV; Metabolic Active Tumor
Keywords: PF ها; Platelet-to-lymphocyte ratio (PLR); Prognosis; Advanced cancer; Meta-analysis; PLR; platelet-to-lymphocyte ratio; OS; overall survival; PFS; progression-free survival; DFS; disease-free survival; CSS; cancer-specific survival; MeSH; Medical Subject Headin
Keywords: PF ها; Immunoassay; Serum biomarker; Cancer; Follow-up; Prognosis; Histotype; HE4; human epididymis protein 4; OC; ovarian cancer; CA125; carbohydrate antigen 125; HR; hazard ratio; PFS; progression-free survival; NCCN; National Comprehensive Cancer Network; GCI
Keywords: PF ها; Cortical folding; Inferior temporal cortex; Fusiform gyrus; Mid-fusiform sulcus; High-level visual cortex; pFs;
Keywords: PF ها; APC; Antigen presenting cells; CIMP; CpG island methylator phenotype; CIN; chromosomal instability; CRC; colorectal cancer; CTLA-4; cytotoxic T lymphocyte-associated protein 4; DAMPs; danger-associated molecular patterns; FDA; US Food and Drug Administr
Keywords: PF ها; Pancreatic adenocarcinoma; Resectable tumor; Laparotomy; Survival; PDAC; Pancreatic ductal adenocarcinoma; OS; overall survival; PFS; progression free survival; DFS; disease free survival; SMV; Superior mesenteric vein; SMA; Superior mesenteric artery; PV
Keywords: PF ها; 5FU; 5-fluorouracil; 95%CI; 95% confidence interval; AA; amino acid; AFP; alpha fetoprotein; AML; actue myeloid leukemia; Ang2; angiopoietin 2; ATP; adenosine triphosphate; BCLC; Barcelona-Clinic Liver Cancer classification; BSC; best supportive care; CAP
Keywords: PF ها; AE; adverse event; ADR; adverse drug reaction; ANC; absolute neutrophil count; CI; confidence interval; CR; complete remission; CTCAE; common terminology criteria for adverse events; DEX; dexamethasone; ECOG; eastern cooperative oncology group; eCRF; elec
Keywords: PF ها; ADT; androgen deprivation therapy; AE; adverse event; CRPC; castration-resistant prostate cancer; LHRH; luteinizing hormone-releasing hormone; mCRPC; metastatic CRPC; MFS; metastase-free survival; nmCRPC; non-metastatic CRPC; PFS; progression-free surviva
Keywords: PF ها; ALA; 5-aminolevulinic acid; BM; Brain metastasis; CT; Computerized tomographic; DFI; Disease free interval; EoR; Extent of resection; FDG; Fludeoxyglucose (18F); IONM; intra-operative neurophysiologic monitoring; KPS; Karnofsky performance score; MRI; Mag
Keywords: PF ها; 5mC; 5- hydroxymethylcytosine; AML; acute myeloid leukemia; BET; bromodomain inhibitors; CCOC; clear cell ovarian cancer; ctDNA; cell-free tumor DNA; ChIP-on-chip; chromatin immunoprecipitation with DNA microarray; CIMP; CpG island methylator phenotype; C
Keywords: PF ها; Intracranial meningioma; Long-term follow-up; Meningioma surgery; Non-skull base meningiomas; Progression-free survival; Recurrence; Skull base meningiomas; Tumor progression rate; EOR; Extent of resection; GTR; Gross total resection; IDM; Incidentally
Keywords: PF ها; A; astrocytoma; AA; anaplastic astrocytoma; AO; anaplastic oligodendroglioma; AOA; anaplastic oligoastrocytoma; EGFR; epidermal growth factor receptor; FISH; fluorescence in situ hybridization; MGMT; O6-methylguanine-DNA methyltransferase; MMP9; matrix me
Keywords: PF ها; AUC; area under the ROC curve; CCA; cholangiocarcinoma; EAC; esophageal adenocarcinoma; ESCC; Esophageal squamous cell carcinoma; FDA; US Food and Drug Administration; FIT; fecal immunochemical test; FOBT; fecal occult blood test; GI; gastrointestinal; HC
Keywords: PF ها; DLBCL; diffuse large B-cell lymphoma; R-CHOP; rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; NHL; non-Hodgkin lymphoma; GEP; gene expression profiling; COO; cell-of-origin; GCB; germinal center B-cell; ABC; activated B-cell; PMBL;
Keywords: PF ها; PC; prostate cancer; mPC; metastatic prostate cancer; ADT; androgen deprivation therapy; CRPC; castration resistant prostate cancer; mCRPC; metastatic CRPC; SNP; single nucleotide polymorphism; CNV; copy number variation; AR; androgen receptor; CTC; circu
Keywords: PF ها; container closure integrity testing; prefilled syringe; primary packaging; mass spectrometry-based helium leak detection; USP <1207>; CCI; container closure integrity; CCS; container closure system; CCIT; container closure integrity testing; DIN; Deutsche
Keywords: PF ها; Chemoprevention; Drug; Insulin Resistance; Pancreas; AMPK; adenosine monophosphate-activated kinase; CI; confidence interval; HR; hazard ratio; mTOR; mechanistic target of rapamycin; OS; overall survival; PFS; progression-free survival; pNET; pancreatic n
Keywords: PF ها; robustness; quality by design; biopharmaceutical; drug product; formulation; manufacturing process; design space; BLA; biological license application; BPDG-FPS; Biophorum Development Group-Formulation Point Share; CQA; critical quality attribute; CPP; c
Keywords: PF ها; uPA; urokinase plasminogen activator; PAI-1; plasminogen activator inhibitor 1; ctDNA; circulating tumor DNA; CTC; circulating tumor cells; PFS; progression-free survival; pCR; pathological complete response; SNVs; single nucleotide variants; CNVs; copy n
Keywords: PF ها; Oxysterols; Cancer; Polymorphism; Risk; Genetics; Cholesterol; 25(OH)D; 25-hydroxyvitamin D; ABC; ATP-binding cassette; AEBS; antiestrogen-binding site; BC; breast cancer; BCR; biochemical recurrence; CETP; cholesteryl ester transfer protein; CH25H; chole
Keywords: PF ها; LDLT; living donor liver transplantation; PFS; portal inflow steal; DDLT; deceased donor liver transplantation; MELD; model for end stage liver disease; US; ultrasonography; CT; computed tomography; GRWR; graft weight to recipient weight ratio; TIPS; tran
Keywords: PF ها; Cytogenetic; Meningiomas; Simpson grade; WHO grade; MRI; Magnetic resonance imaging; PFS; Progression-free survival; SFRT; Stereotactic fractionated radiotherapy; WHO; World Health Organization;
Keywords: PF ها; NSCLC; non small-cell lung cancer; EGFR; epidermal growth factor receptor; TKI; tyrosine kinase inhibitor; PFS; progression-free survival; ECOG; Eastern Cooperative Oncology Group; RECIST; Response Evaluation Criteria in Solid Tumors; ECG; electrocardiogr
Keywords: PF ها; Low dose; Metronomic chemotherapy; Metastatic colorectal cancer; CRC; colorectal cancer; mCRC; metastatic colorectal cancer; MTD; maximal tolerated dose; PFS; progression-free survival; OS; overall survival; TSP-1; thrombospondin-1;
Keywords: PF ها; ARC; arcuate nucleus; BW; body weight; COX; cyclooxygenase; DMH; dorso-medial, nucleus; FI; food intake; GALP; galanin-like peptide; ICV; Intracerebroventricular; IP; intraperitoneal; LH; lateral hypothalamus; MR; metabolic rate; NPY; neuropeptide Y; PFS;